Mocravimod improves overall survival in AML patients undergoing allogeneic hematopoietic cell transplantation https://priothera.com/mocravimod-improves-overall-survival-in-aml-patients-undergoing-allogeneic-hematopoietic-cell-transplantation/
Mocravimod, an S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation https://priothera.com/mocravimod-a-s1p-receptor-modulator-increases-t-cell-counts-in-bone-marrow-biopsies-from-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation/
Mocravimod ameliorates chronic graft-versus-host disease after mouse allogeneic HCT https://priothera.com/mocravimod-ameliorates-chronic-graft-versus-host-disease-after-mouse-allogeneic-hct/
Mocravimod, a selective sphingosine-1-phosphate receptor modulator, in allogeneic hematopoietic cell transplantation for malignancy https://priothera.com/mocravimod-a-selective-sphingosine-1-phosphate-receptor-modulator-in-allogeneic-hematopoietic-cell-transplantation-for-malignancy/
A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of KRP203 in subjects with hematological malignancies undergoing allogeneic hematopoietic cell transplantation https://priothera.com/a-two-part-single-and-two-arm-randomized-open-label-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-krp203-in-subjects-with-hematological-malignancies-undergoing-allogeneic-hemat/
Recent Comments